Bjørn Allan Moum
- Professor, Consultant of Gastroenterology; MD, PhD
- +47 450 65 275
Education:
- MD University of Århus Denmark 1980
- Dr med University of Oslo (1997)
- Norwegian clinical specialist accreditations
Internal medicine and gastroenterology (1991)
Current position:
- Professor University of Oslo
- Consultant, Department of gastroenterology, Oslo University Hospital
Publications 2024
Frailty risk and treatment strategy in elderly-onset inflammatory bowel disease. A Norwegian nationwide population-based registry study
Dig Liver Dis, 56 (9), 1503-1510
DOI 10.1016/j.dld.2024.02.002, PubMed 38433021
Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study
Crohns Colitis 360, 6 (1), otae013
DOI 10.1093/crocol/otae013, PubMed 38544907
Publications 2023
The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission
Lancet Gastroenterol Hepatol, 8 (5), 458-492
DOI 10.1016/S2468-1253(23)00003-1, PubMed 36871566
Mortality in Patients with Inflammatory Bowel Disease: Results from 30 Years of Follow-up in a Norwegian Inception Cohort (the IBSEN study)
J Crohns Colitis, 17 (4), 497-503
DOI 10.1093/ecco-jcc/jjac156, PubMed 36239614
Risk of Cancer in Patients With Crohn's Disease 30 Years After Diagnosis (the IBSEN Study)
Crohns Colitis 360, 5 (4), otad057
DOI 10.1093/crocol/otad057, PubMed 37886706
Incidence of cancer in patients with ulcerative colitis 30 years after diagnosis (the IBSEN study)
Scand J Gastroenterol, 58 (11), 1264-1270
DOI 10.1080/00365521.2023.2223709, PubMed 37337889
The Real-World Global Use of Patient-Reported Outcomes for the Care of Patients With Inflammatory Bowel Disease
Crohns Colitis 360, 5 (2), otad006
DOI 10.1093/crocol/otad006, PubMed 36937140
Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring
Scand J Gastroenterol, 58 (8), 863-873
DOI 10.1080/00365521.2023.2176252, PubMed 36799155
Publications 2022
The multidimensional fatigue inventory (MFI-20): psychometrical testing in a Norwegian sample of inflammatory bowel disease (IBD) patients
Scand J Gastroenterol, 1-7 (in press)
DOI 10.1080/00365521.2022.2029939, PubMed 35076321
[Iron deficiency in patients with acute and chronic heart failure - a simple algoritm]
Lakartidningen, 119
PubMed 36149233
The impact of restrictions on psychological outcomes in patients with inflammatory bowel disease on biological treatment during the coronavirus pandemic in Norway
Qual Life Res, 32 (3), 691-699
DOI 10.1007/s11136-022-03254-4, PubMed 36125603
Therapeutic management and outcomes in inflammatory bowel diseases, 2010 to 2017 in cohorts from Denmark, Sweden and Norway
Aliment Pharmacol Ther, 56 (6), 989-1006
DOI 10.1111/apt.17145, PubMed 35902223
Publications 2021
First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study
Scand J Gastroenterol, 56 (10), 1163-1168
DOI 10.1080/00365521.2021.1955147, PubMed 34320885
Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact
World J Gastroenterol, 27 (17), 2039-2053
DOI 10.3748/wjg.v27.i17.2039, PubMed 34007138
Incidence and Prevalence of Inflammatory Bowel Disease in Norway and the Impact of Different Case Definitions: A Nationwide Registry Study
Clin Epidemiol, 13, 287-294
DOI 10.2147/CLEP.S303797, PubMed 33935519
Outcome of Ulcerative Colitis 20 Years after Diagnosis in a Prospective Population-based Inception Cohort from South-Eastern Norway, the IBSEN Study
J Crohns Colitis, 15 (6), 969-979
DOI 10.1093/ecco-jcc/jjaa232, PubMed 33367569
Patients with inflammatory bowel disease on immunosuppressive drugs: perspectives' on COVID-19 and health care service during the pandemic
Scand J Gastroenterol, 56 (5), 545-551
DOI 10.1080/00365521.2021.1901308, PubMed 33771086
Publications 2020
Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis
Clin Gastroenterol Hepatol, 18 (10), 2295-2304.e2
DOI 10.1016/j.cgh.2020.02.014, PubMed 32068151
Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials
BioDrugs, 34 (5), 681-694
DOI 10.1007/s40259-020-00438-7, PubMed 32965617
Risk of colorectal cancer in a population-based study 20 years after diagnosis of ulcerative colitis: results from the IBSEN study
BMJ Open Gastroenterol, 7 (1), e000361
DOI 10.1136/bmjgast-2019-000361, PubMed 32337058
Association of Childbearing With a Short-Term Reduced Risk of Crohn Disease in Mothers
Am J Epidemiol, 189 (4), 294-304
DOI 10.1093/aje/kwz285, PubMed 31907543
Serological antibodies and surgery in a population-based inception cohort of Crohn's disease patients - the IBSEN study
Scand J Gastroenterol, 55 (4), 436-441
DOI 10.1080/00365521.2020.1745879, PubMed 32252542
[Chronic inflammatory bowel disease and COVID-19]
Tidsskr Nor Laegeforen, 140 (7)
DOI 10.4045/tidsskr.20.0230, PubMed 32378846
Self-esteem in patients with inflammatory bowel disease
Qual Life Res, 29 (7), 1839-1846
DOI 10.1007/s11136-020-02467-9, PubMed 32144613
The Impact of Spondyloarthritis and Joint Symptoms on Health-Related Quality of Life and Fatigue in IBD Patients. Results From a Population-Based Inception Cohort (20-Year Follow-up in the Ibsen Study)
Inflamm Bowel Dis, 26 (1), 114-124
DOI 10.1093/ibd/izz105, PubMed 31127829
Comprehensive assessment of ECM turnover using serum biomarkers establishes PBC as a high-turnover autoimmune liver disease
JHEP Rep, 3 (1), 100178
DOI 10.1016/j.jhepr.2020.100178, PubMed 33225252
Publications 2019
Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort
Scand J Gastroenterol, 54 (1), 41-48
DOI 10.1080/00365521.2018.1548646, PubMed 30650312
Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside
Aliment Pharmacol Ther, 50 (4), 397-406
DOI 10.1111/apt.15386, PubMed 31264261
Pain Severity and Vitamin D Deficiency in IBD Patients
Nutrients, 12 (1)
DOI 10.3390/nu12010026, PubMed 31877637
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial
J Intern Med, 285 (6), 653-669
DOI 10.1111/joim.12880, PubMed 30762274
Publications 2018
Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series
Inflamm Bowel Dis, 24 (5), 997-1004
DOI 10.1093/ibd/izx110, PubMed 29668901
Circulating markers of gut barrier function associated with disease severity in primary sclerosing cholangitis
Liver Int, 39 (2), 371-381
DOI 10.1111/liv.13979, PubMed 30269440
Anemia following Roux-en-Y gastric bypass for morbid obesity; a 5-year follow-up study
Scand J Gastroenterol, 53 (8), 917-922
DOI 10.1080/00365521.2018.1489892, PubMed 30231804
Fatigue is not associated with vitamin D deficiency in inflammatory bowel disease patients
World J Gastroenterol, 24 (29), 3293-3301
DOI 10.3748/wjg.v24.i29.3293, PubMed 30090009
Irritable Bowel-like Symptoms in Ulcerative Colitis are as Common in Patients in Deep Remission as in Inflammation: Results From a Population-based Study [the IBSEN Study]
J Crohns Colitis, 12 (4), 389-393
DOI 10.1093/ecco-jcc/jjx152, PubMed 29186372
Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population
Scand J Gastroenterol, 53 (6), 692-699
DOI 10.1080/00365521.2018.1463391, PubMed 29852793
Analysis of DNA Methylation at Specific Loci in Stool Samples Detects Colorectal Cancer and High-Grade Dysplasia in Patients With Inflammatory Bowel Disease
Clin Gastroenterol Hepatol, 17 (5), 914-921.e5
DOI 10.1016/j.cgh.2018.05.004, PubMed 29775793
Multi-target stool DNA test in the surveillance of inflammatory bowel disease: a cross-sectional cohort study
Scand J Gastroenterol, 53 (3), 273-278
DOI 10.1080/00365521.2018.1424935, PubMed 29313389
Real-life chromoendoscopy for dysplasia surveillance in ulcerative colitis
World J Gastroenterol, 24 (35), 4069-4076
DOI 10.3748/wjg.v24.i35.4069, PubMed 30254411
Regional differences in anti-TNF-α therapy and surgery in the treatment of inflammatory bowel disease patients: a Norwegian nationwide cohort study
Scand J Gastroenterol, 53 (8), 952-957
DOI 10.1080/00365521.2018.1495258, PubMed 30205699
Serological markers of extracellular matrix remodeling predict transplant-free survival in primary sclerosing cholangitis
Aliment Pharmacol Ther, 48 (2), 179-189
DOI 10.1111/apt.14806, PubMed 29851098
Peripheral arthritis in patients with long-term inflammatory bowel disease. Results from 20 years of follow-up in the IBSEN study
Scand J Gastroenterol, 53 (10-11), 1250-1256
DOI 10.1080/00365521.2018.1518482, PubMed 30353756
Ankylosing Spondylitis and Axial Spondyloarthritis in Patients With Long-term Inflammatory Bowel Disease: Results From 20 Years of Follow-up in the IBSEN Study
J Crohns Colitis, 12 (1), 96-104
DOI 10.1093/ecco-jcc/jjx126, PubMed 28961700
Sex-Based Differences in Incidence of Inflammatory Bowel Diseases-Pooled Analysis of Population-Based Studies From Western Countries
Gastroenterology, 155 (4), 1079-1089.e3
DOI 10.1053/j.gastro.2018.06.043, PubMed 29958857
Publications 2017
Does the Introduction of Biosimilars Change Our Understanding about Treatment Modalities for Inflammatory Bowel Disease?
Dig Dis, 35 (1-2), 74-82
DOI 10.1159/000449087, PubMed 28147370
Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study
J Crohns Colitis, 11 (3), 297-304
DOI 10.1093/ecco-jcc/jjw166, PubMed 27660339
Occurrence of Anaemia in the First Year of Inflammatory Bowel Disease in a European Population-based Inception Cohort-An ECCO-EpiCom Study
J Crohns Colitis, 11 (10), 1213-1222
DOI 10.1093/ecco-jcc/jjx077, PubMed 28575481
Corrigendum: Malignancies in Patients with Inflammatory Bowel Disease (IBD): Results from 20 Years of Follow-up in the IBSEN (Inflammatory Bowel South-Eastern Norway) Study
J Crohns Colitis, 11 (12), 1511
DOI 10.1093/ecco-jcc/jjw218, PubMed 28039308
Malignancies in Patients with Inflammatory Bowel Disease: Results from 20 Years of Follow-up in the IBSEN Study
J Crohns Colitis, 11 (5), 571-577
DOI 10.1093/ecco-jcc/jjw193, PubMed 28453756
Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis
Gastroenterol Res Pract, 2017, 2098293
DOI 10.1155/2017/2098293, PubMed 29225617
Psychometric limitations of the 13-item Sense of Coherence Scale assessed by Rasch analysis
BMC Psychol, 5 (1), 18
DOI 10.1186/s40359-017-0187-y, PubMed 28595651
Guanylate Cyclase C Activation Shapes the Intestinal Microbiota in Patients with Familial Diarrhea and Increased Susceptibility for Crohn's Disease
Inflamm Bowel Dis, 23 (10), 1752-1761
DOI 10.1097/MIB.0000000000001264, PubMed 28902124
Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis
J Hepatol, 66 (6), 1214-1222
DOI 10.1016/j.jhep.2017.01.019, PubMed 28161472
Publications 2016
Fluoride: a risk factor for inflammatory bowel disease?
Scand J Gastroenterol, 51 (9), 1019-24
DOI 10.1080/00365521.2016.1177855, PubMed 27199224
Vitamin D deficiency in inflammatory bowel disease: prevalence and predictors in a Norwegian outpatient population
Scand J Gastroenterol, 52 (1), 100-106
DOI 10.1080/00365521.2016.1233577, PubMed 27603182
Mortality and Causes of Death in Ulcerative Colitis: Results from 20 Years of Follow-up in the IBSEN Study
Inflamm Bowel Dis, 22 (1), 141-5
DOI 10.1097/MIB.0000000000000582, PubMed 26355464
Fatigue in a population-based cohort of patients with inflammatory bowel disease 20 years after diagnosis: The IBSEN study
Scand J Gastroenterol, 52 (3), 351-358
DOI 10.1080/00365521.2016.1256425, PubMed 27852169
Health-related Quality of Life in Patients with Inflammatory Bowel Disease 20 Years After Diagnosis: Results from the IBSEN Study
Inflamm Bowel Dis, 22 (7), 1679-87
DOI 10.1097/MIB.0000000000000806, PubMed 27206016
Comparison of the Multiattribute Utility Instruments EQ-5D and SF-6D in a Europe-Wide Population-Based Cohort of Patients with Inflammatory Bowel Disease 10 Years after Diagnosis
Gastroenterol Res Pract, 2016, 5023973
DOI 10.1155/2016/5023973, PubMed 27630711
Pain may be an important factor to consider in inflammatory bowel disease patients troubled by fatigue
United European Gastroenterol J, 5 (5), 687-693
DOI 10.1177/2050640616674654, PubMed 28815032
Validity, Reliability, and Responsiveness of the Brief Pain Inventory in Inflammatory Bowel Disease
Can J Gastroenterol Hepatol, 2016, 5624261
DOI 10.1155/2016/5624261, PubMed 27446848
Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation
Mucosal Immunol, 9 (6), 1455-1465
DOI 10.1038/mi.2016.18, PubMed 26982597
Patient-performed extraction of faecal calprotectin
Clin Chem Lab Med, 54 (8), 1357-63
DOI 10.1515/cclm-2015-1037, PubMed 26812797
The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls
Gut, 66 (4), 611-619
DOI 10.1136/gutjnl-2015-310500, PubMed 26887816
Elevated trimethylamine-N-oxide (TMAO) is associated with poor prognosis in primary sclerosing cholangitis patients with normal liver function
United European Gastroenterol J, 5 (4), 532-541
DOI 10.1177/2050640616663453, PubMed 28588885
Prevalence of Sclerosing Cholangitis Detected by Magnetic Resonance Cholangiography in Patients With Long-term Inflammatory Bowel Disease
Gastroenterology, 151 (4), 660-669.e4
DOI 10.1053/j.gastro.2016.06.021, PubMed 27342213
The Use of Complementary and Alternative Medicine among Patients with Inflammatory Bowel Disease Is Associated with Reduced Health-Related Quality of Life
Gastroenterol Res Pract, 2016, 6453657
DOI 10.1155/2016/6453657, PubMed 28003821
Development of an index to define overall disease severity in IBD
Gut, 67 (2), 244-254
DOI 10.1136/gutjnl-2016-312648, PubMed 27780886
Predictive factors for a severe clinical course in ulcerative colitis: Results from population-based studies
World J Gastrointest Pharmacol Ther, 7 (2), 235-41
DOI 10.4292/wjgpt.v7.i2.235, PubMed 27158539
Publications 2015
[Iron deficiency and iron deficiency anemia are global health problems]
Lakartidningen, 112
PubMed 25756711
Health-related quality of life in inflammatory bowel disease in a European-wide population-based cohort 10 years after diagnosis
Inflamm Bowel Dis, 21 (2), 337-44
DOI 10.1097/MIB.0000000000000272, PubMed 25569735
Patients' perceptions of quality of care and follow-up in inflammatory bowel disease
Scand J Gastroenterol, 51 (4), 434-41
DOI 10.3109/00365521.2015.1102319, PubMed 26635189
Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin
J Crohns Colitis, 9 (2), 164-9
DOI 10.1093/ecco-jcc/jju015, PubMed 25518057
Validation of a new extraction device for measuring faecal calprotectin in inflammatory bowel disease, and comparison to established extraction methods
Scand J Clin Lab Invest, 75 (5), 355-61
DOI 10.3109/00365513.2015.1030765, PubMed 25856663
Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure
Scand J Gastroenterol, 51 (5), 548-55
DOI 10.3109/00365521.2015.1117650, PubMed 26634305
Correspondence: fecal calprotectin and cut-off levels in inflammatory bowel disease
Scand J Gastroenterol, 50 (9), 1183-4
DOI 10.3109/00365521.2015.1025830, PubMed 25772406
Challenges in the care of IBD in patients of all ages
Tidsskr. Nor. Laegeforen., 135 (2), 157
DOI 10.4045/tidsskr.14.1267
Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients (the IBSEN study)
Scand J Gastroenterol, 50 (12), 1456-62
DOI 10.3109/00365521.2015.1064991, PubMed 26139389
Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis
Hepatology, 62 (1), 188-97
DOI 10.1002/hep.27825, PubMed 25833813
Publications 2014
Prevalence of anemia in inflammatory bowel diseases in european countries: a systematic review and individual patient data meta-analysis
Inflamm Bowel Dis, 20 (5), 936-45
DOI 10.1097/01.MIB.0000442728.74340.fd, PubMed 24572205
Letter: European Medicines Agency recommendations for allergic reactions to intravenous iron-containing medicines
Aliment Pharmacol Ther, 39 (7), 743-4
DOI 10.1111/apt.12648, PubMed 24588280
Thromboembolism in inflammatory bowel disease: results from a prospective, population-based European inception cohort
Scand J Gastroenterol, 49 (7), 820-5
DOI 10.3109/00365521.2014.910545, PubMed 24754745
Extraintestinal manifestations in Crohn's disease and ulcerative colitis: results from a prospective, population-based European inception cohort
Scand J Gastroenterol, 50 (3), 300-5
DOI 10.3109/00365521.2014.991752, PubMed 25535653
Coexisting irritable bowel-like symptoms in inflammatory bowel disease in remission is associated with impaired social functioning and increased bodily pain
Gastroenterol Nurs, 37 (4), 280-7
DOI 10.1097/SGA.0000000000000055, PubMed 25078042
Faecal calprotectin levels differentiate intestinal from pulmonary tuberculosis: An observational study from Southern India
United European Gastroenterol J, 2 (5), 397-405
DOI 10.1177/2050640614546947, PubMed 25360318
High faecal calprotectin levels in intestinal tuberculosis are associated with granulomas in intestinal biopsies
Infect Dis (Lond), 47 (3), 137-43
DOI 10.3109/00365548.2014.974206, PubMed 25522183
Routine diagnosis of intestinal tuberculosis and Crohn's disease in Southern India
World J Gastroenterol, 20 (17), 5017-24
DOI 10.3748/wjg.v20.i17.5017, PubMed 24803814
Clinical course and prognosis in ulcerative colitis: results from population-based and observational studies
Ann Gastroenterol, 27 (2), 95-104
PubMed 24733679
What have we learnt about the role of the environment and natural course of IBD in the new millennium? 20-year follow-up of the IBSEN cohort
Dig Dis, 32 Suppl 1, 2-9
DOI 10.1159/000367818, PubMed 25531347
Biosimilar medicines in inflammatory bowel disease
Tidsskr Nor Laegeforen, 134 (8), 819-20
DOI 10.4045/tidsskr.14.0192, PubMed 24780979
Sense of coherence in patients with inflammatory bowel disease
Gastroenterol Res Pract, 2014, 989038
DOI 10.1155/2014/989038, PubMed 24527028
Risk matrix for prediction of advanced disease in a population-based study of patients with Crohn's Disease (the IBSEN Study)
Inflamm Bowel Dis, 20 (1), 60-8
DOI 10.1097/01.MIB.0000436956.78220.67, PubMed 24280875
Publications 2013
High burden of iron deficiency and different types of anemia in inflammatory bowel disease outpatients in Scandinavia: a longitudinal 2-year follow-up study
Scand J Gastroenterol, 48 (11), 1286-93
DOI 10.3109/00365521.2013.838605, PubMed 24073709
A review of mortality and surgery in ulcerative colitis: milestones of the seriousness of the disease
Inflamm Bowel Dis, 19 (9), 2001-10
DOI 10.1097/MIB.0b013e318281f3bb, PubMed 23624887
Mortality and causes of death in Crohn's disease: results from 20 years of follow-up in the IBSEN study
Gut, 63 (5), 771-5
DOI 10.1136/gutjnl-2013-304766, PubMed 23744613
Anaemia in inflammatory bowel disease: a population-based 10-year follow-up
Aliment Pharmacol Ther, 39 (1), 69-76
DOI 10.1111/apt.12541, PubMed 24172277
Calprotectin Is a Useful Tool in Distinguishing Coexisting Irritable Bowel-Like Symptoms from That of Occult Inflammation among Inflammatory Bowel Disease Patients in Remission
Gastroenterol Res Pract, 2013, 620707
DOI 10.1155/2013/620707, PubMed 23476638
Geographical variability and environmental risk factors in inflammatory bowel disease
Gut, 62 (4), 630-49
DOI 10.1136/gutjnl-2012-303661, PubMed 23335431
Fatigue interference with daily living among patients with inflammatory bowel disease
Qual Life Res, 23 (2), 707-17
DOI 10.1007/s11136-013-0508-4, PubMed 23975381
The management of iron deficiency in inflammatory bowel disease--an online tool developed by the RAND/UCLA appropriateness method
Aliment Pharmacol Ther, 38 (9), 1109-18
DOI 10.1111/apt.12493, PubMed 24099472
Publications 2012
Hospitalisations and surgery in Crohn's disease
Gut, 61 (4), 622-9
DOI 10.1136/gutjnl-2011-301397, PubMed 22267595
[A woman in her 60s with multifactorial anaemia]
Tidsskr Nor Laegeforen, 132 (8), 965-8
DOI 10.4045/tidsskr.10.1449, PubMed 22562330
Epidemiology and clinical course of Crohn's disease: results from observational studies
World J Gastroenterol, 18 (15), 1723-31
DOI 10.3748/wjg.v18.i15.1723, PubMed 22553396
Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study
Gut, 62 (3), 368-75
DOI 10.1136/gutjnl-2012-302311, PubMed 22717453
Chronic fatigue is associated with increased disease-related worries and concerns in inflammatory bowel disease
World J Gastroenterol, 18 (5), 445-52
DOI 10.3748/wjg.v18.i5.445, PubMed 22346250
Is patient reported outcome (PRO) affected by different follow-up regimens in inflammatory bowel disease (IBD)? A one year prospective, longitudinal comparison of nurse-led versus conventional follow-up
J Crohns Colitis, 6 (9), 887-94
DOI 10.1016/j.crohns.2012.01.021, PubMed 22398072
Fatigue and disease-related worries among inflammatory bowel disease patients in remission; is it a reflection of coexisting IBS-like symptoms? A short report
J Psychosom Res, 73 (6), 469-72
DOI 10.1016/j.jpsychores.2012.08.009, PubMed 23148817
Randomised clinical trial: a comparison between a GerdQ-based algorithm and an endoscopy-based approach for the diagnosis and initial treatment of GERD
Aliment Pharmacol Ther, 35 (11), 1290-300
DOI 10.1111/j.1365-2036.2012.05092.x, PubMed 22510027
Cancer in inflammatory bowel disease 15 years after diagnosis in a population-based European Collaborative follow-up study (vol 5, pg 430, 2011)
J. Crohns Colitis, 6 (1), 132-133
DOI 10.1016/j.crohns.2011.11.023
Use of complementary and alternative medicine in patients with inflammatory bowel disease: results of a cross-sectional study in Norway
Scand J Gastroenterol, 47 (12), 1436-47
DOI 10.3109/00365521.2012.725092, PubMed 23003678
Publications 2011
Fatigue in out-patients with inflammatory bowel disease is common and multifactorial
Aliment Pharmacol Ther, 35 (1), 133-41
DOI 10.1111/j.1365-2036.2011.04914.x, PubMed 22059387
Health-related quality of life in patients with ulcerative colitis after a 10-year disease course: results from the IBSEN study
Inflamm Bowel Dis, 18 (8), 1540-9
DOI 10.1002/ibd.21863, PubMed 21936030
Patients with Crohn's disease experience reduced general health and vitality in the chronic stage: ten-year results from the IBSEN study
J Crohns Colitis, 6 (4), 441-53
DOI 10.1016/j.crohns.2011.10.001, PubMed 22398064
Quality of life in patients with inflammatory bowel disease: translation, validity, reliability and sensitivity to change of the Norwegian version of the short health scale (SHS)
Qual Life Res, 21 (9), 1671-6
DOI 10.1007/s11136-011-0081-7, PubMed 22146840
Worries and Concerns among Inflammatory Bowel Disease Patients Followed Prospectively over One Year
Gastroenterol Res Pract, 2011, 492034
DOI 10.1155/2011/492034, PubMed 21912537
Measuring health-related quality of life in non-complicated diabetes patients may be an effective parameter to assess patients at risk of a more serious disease course: a cross-sectional study of two diabetes outpatient groups
J Clin Nurs, 20 (9-10), 1255-63
DOI 10.1111/j.1365-2702.2010.03554.x, PubMed 21401763
Cancer in inflammatory bowel disease 15 years after diagnosis in a population-based European Collaborative follow-up study
J Crohns Colitis, 5 (5), 430-42
DOI 10.1016/j.crohns.2011.04.013, PubMed 21939917
Complementary and alternative medicine in patients with inflammatory bowel disease: the results of a population-based inception cohort study (IBSEN)
J Crohns Colitis, 6 (3), 345-53
DOI 10.1016/j.crohns.2011.09.007, PubMed 22405172
Publications 2010
The prevalence of anemia and iron deficiency in IBD outpatients in Scandinavia
Scand J Gastroenterol, 46 (3), 304-9
DOI 10.3109/00365521.2010.533382, PubMed 21073374
Relationships between inflammatory bowel disease and perinatal factors: both maternal and paternal disease are related to preterm birth of offspring
Inflamm Bowel Dis, 16 (5), 847-55
DOI 10.1002/ibd.21120, PubMed 19795509
[Proton pump inhibitors do not cause stomach cancer]
Tidsskr Nor Laegeforen, 130 (6), 592
DOI 10.4045/tidsskr.10.0084, PubMed 20348996
Need for standardization in population-based quality of life studies: a review of the current literature
Inflamm Bowel Dis, 16 (3), 525-36
DOI 10.1002/ibd.21032, PubMed 19637337
Chronic fatigue is associated with impaired health-related quality of life in inflammatory bowel disease
Aliment Pharmacol Ther, 33 (1), 106-14
DOI 10.1111/j.1365-2036.2010.04498.x, PubMed 21083587
Chronic fatigue is more prevalent in patients with inflammatory bowel disease than in healthy controls
Inflamm Bowel Dis, 17 (7), 1564-72
DOI 10.1002/ibd.21530, PubMed 21674713
[When should anti-TNF-alpha treatment in Crohn disease be terminated?]
Tidsskr Nor Laegeforen, 130 (5), 474
DOI 10.4045/tidsskr.09.1526, PubMed 20224609
[Obesity surgery in inflammatory bowel disease]
Tidsskr Nor Laegeforen, 130 (6), 638-9
DOI 10.4045/tidsskr.09.1281, PubMed 20349013
Fecal calprotectin variability in Crohn's disease
Inflamm Bowel Dis, 16 (7), 1091-2
DOI 10.1002/ibd.21136, PubMed 19834972
Publications 2009
Clustering in time of familial IBD separates ulcerative colitis from Crohn's disease
Inflamm Bowel Dis, 15 (12), 1867-74
DOI 10.1002/ibd.20978, PubMed 19434721
Clinical and economic outcomes in a population-based European cohort of 948 ulcerative colitis and Crohn's disease patients by Markov analysis
Aliment Pharmacol Ther, 31 (7), 735-44
DOI 10.1111/j.1365-2036.2009.04228.x, PubMed 20047578
Predictive value of serologic markers in a population-based Norwegian cohort with inflammatory bowel disease
Inflamm Bowel Dis, 15 (3), 406-14
DOI 10.1002/ibd.20781, PubMed 19009607
Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)
Scand J Gastroenterol, 44 (4), 431-40
DOI 10.1080/00365520802600961, PubMed 19101844
[Surgery, inflammatory bowel disease and biological treatment]
Tidsskr Nor Laegeforen, 129 (22), 2389-90
DOI 10.4045/tidsskr.09.1231, PubMed 19935950
Publications 2008
Familial aggregation in Crohn's disease and ulcerative colitis in a Norwegian population-based cohort followed for ten years
J Crohns Colitis, 3 (2), 92-9
DOI 10.1016/j.crohns.2008.11.002, PubMed 21172251
C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study
Gut, 57 (11), 1518-23
DOI 10.1136/gut.2007.146357, PubMed 18566104
Appendectomy and inflammatory bowel disease: The end of a dogma? Reply
Am. J. Gastroenterol., 103 (2), 492
DOI 10.1111/j.1572-0241.2007.01646_12.x
Which are the 5-ASA compound side effects and how is it possible to avoid them?
Inflamm Bowel Dis, 14 Suppl 2, S212-3
DOI 10.1002/ibd.20712, PubMed 18816767
The association between water supply and inflammatory bowel disease based on a 1990-1993 cohort study in southeastern Norway
Am J Epidemiol, 168 (9), 1065-72
DOI 10.1093/aje/kwn218, PubMed 18801890
Geographic distribution and ecological studies of inflammatory bowel disease in southeastern Norway in 1990-1993
Inflamm Bowel Dis, 14 (7), 984-91
DOI 10.1002/ibd.20417, PubMed 18338775
Publications 2007
Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort
Gastroenterology, 133 (2), 412-22
DOI 10.1053/j.gastro.2007.05.051, PubMed 17681162
Are there any differences in phenotype or disease course between familial and sporadic cases of inflammatory bowel disease? Results of a population-based follow-up study
Am J Gastroenterol, 102 (9), 1955-63
DOI 10.1111/j.1572-0241.2007.01368.x, PubMed 17573793
Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study)
Scand J Gastroenterol, 42 (5), 602-10
DOI 10.1080/00365520601076124, PubMed 17454881
[Colorectal cancer in inflammatory bowel disease]
Tidsskr Nor Laegeforen, 127 (20), 2696-9
PubMed 17952155
Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort
Am J Gastroenterol, 102 (8), 1692-701
DOI 10.1111/j.1572-0241.2007.01265.x, PubMed 17555460
Serological markers are associated with disease course in ulcerative colitis. A study in an unselected population-based cohort followed for 10 years
J Crohns Colitis, 2 (2), 114-22
DOI 10.1016/j.crohns.2007.10.001, PubMed 21172201
Dysplasia and cancer in inflammatory bowel disease 10 years after diagnosis: results of a population-based European collaborative follow-up study
Digestion, 75 (2-3), 113-21
DOI 10.1159/000104731, PubMed 17598963
[When can TNF-alpha inhibitors against inflammatory bowel disease be withdrawn?]
Tidsskr Nor Laegeforen, 127 (12), 1673
PubMed 17571118
[Follow up of the use of biological drugs against inflammatory bowel diseases]
Tidsskr Nor Laegeforen, 127 (21), 2841-2
PubMed 17987080
Occurrence of hepatoxicicty and elevated liver enzymes in a Crohn's disease patient treated with infliximab
Inflamm Bowel Dis, 13 (12), 1584-6
DOI 10.1002/ibd.20230, PubMed 17663423
Role of ASCA and the NOD2/CARD15 mutation Gly908Arg in predicting increased surgical costs in Crohn's disease patients: a project of the European Collaborative Study Group on Inflammatory Bowel Disease
Inflamm Bowel Dis, 13 (7), 874-81
DOI 10.1002/ibd.20122, PubMed 17278126
Effect of phenotype on health care costs in Crohn's disease: A European study using the Montreal classification
J Crohns Colitis, 1 (2), 87-96
DOI 10.1016/j.crohns.2007.08.004, PubMed 21172190
The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients
Inflamm Bowel Dis, 13 (1), 24-32
DOI 10.1002/ibd.20047, PubMed 17206636
Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study
Clin Gastroenterol Hepatol, 5 (12), 1430-8
DOI 10.1016/j.cgh.2007.09.002, PubMed 18054751
Treatment inferred disease severity in Crohn's disease: evidence for a European gradient of disease course
Scand J Gastroenterol, 42 (3), 333-44
DOI 10.1080/00365520600930750, PubMed 17354113
Publications 2006
Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease
Inflamm Bowel Dis, 12 (5), 402-12
DOI 10.1097/01.MIB.0000218762.61217.4a, PubMed 16670530
Long-term management of patients with symptoms of gastro-oesophageal reflux disease -- a Norwegian randomised prospective study comparing the effects of esomeprazole and ranitidine treatment strategies on health-related quality of life in a general practitioners setting
Int J Clin Pract, 60 (1), 15-22
DOI 10.1111/j.1368-5031.2006.00768.x, PubMed 16409423
Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study)
Inflamm Bowel Dis, 12 (7), 543-50
DOI 10.1097/01.MIB.0000225339.91484.fc, PubMed 16804390
Change of diagnosis during the first five years after onset of inflammatory bowel disease: results of a prospective follow-up study (the IBSEN Study)
Scand J Gastroenterol, 41 (9), 1037-43
DOI 10.1080/00365520600554527, PubMed 16938716
Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years
Gastroenterology, 132 (2), 507-15
DOI 10.1053/j.gastro.2006.11.015, PubMed 17258717
Ulcerative colitis: no rise in mortality in a European-wide population based cohort 10 years after diagnosis
Gut, 56 (4), 497-503
DOI 10.1136/gut.2006.101519, PubMed 17028127
Extreme heterogeneity in CARD15 and DLG5 Crohn disease-associated polymorphisms between German and Norwegian populations
Eur J Hum Genet, 14 (4), 459-68
DOI 10.1038/sj.ejhg.5201576, PubMed 16493449
[New drug financing model causes concerns]
Tidsskr Nor Laegeforen, 126 (21), 2830
PubMed 17086229
Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation
Gastroenterology, 131 (3), 719-28
DOI 10.1053/j.gastro.2006.05.052, PubMed 16952541
Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. (vol 131, pg 719, 2006)
Gastroenterology, 131 (6), 2029
Does pregnancy change the disease course? A study in a European cohort of patients with inflammatory bowel disease
Am J Gastroenterol, 101 (7), 1539-45
DOI 10.1111/j.1572-0241.2006.00602.x, PubMed 16863558
[Stent insertion as palliation of cancer in the esophagus and cardia]
Tidsskr Nor Laegeforen, 126 (12), 1607-9
PubMed 16770371
Trondheim gartnerforening 100 år: 1906-2006
[Trondheim gartnerforening], [Trondheim], 147 s.
BIBSYS 061561797
Disease outcome of inflammatory bowel disease patients: general outline of a Europe-wide population-based 10-year clinical follow-up study
Scand J Gastroenterol Suppl (243), 46-54
DOI 10.1080/00365520600664250, PubMed 16782622
Publications 2005
Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms
Inflamm Bowel Dis, 11 (10), 909-18
DOI 10.1097/01.mib.0000179467.01748.99, PubMed 16189421
Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis
Eur J Gastroenterol Hepatol, 17 (10), 1037-45
DOI 10.1097/00042737-200510000-00006, PubMed 16148548
Six-month management of patients following treatment for gastroesophageal reflux disease symptoms -- a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical practitioners setting
Int J Clin Pract, 59 (6), 655-64
DOI 10.1111/j.1368-5031.2005.00563.x, PubMed 15924593
Ulcerative colitis, colorectal cancer and colonoscopic surveillance
Scand J Gastroenterol, 40 (8), 881-5
DOI 10.1080/00365520510023701, PubMed 16170896
A randomised prospective study comparing the effectiveness of esomeprazole treatment strategies in clinical practice for 6 months in the management of patients with symptoms of gastroesophageal reflux disease
Int J Clin Pract, 59 (6), 665-71
DOI 10.1111/j.1368-5031.2005.00564.x, PubMed 15924594
Non-inflammatory joint pain in patients with inflammatory bowel disease is prevalent and has a significant impact on health related quality of life
J Rheumatol, 32 (9), 1755-9
PubMed 16142874
Phenotype at diagnosis predicts recurrence rates in Crohn's disease
Gut, 55 (8), 1124-30
DOI 10.1136/gut.2005.084061, PubMed 16361306
Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort
Gut, 55 (4), 510-8
DOI 10.1136/gut.2005.072793, PubMed 16150857
Publications 2004
The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole
Aliment Pharmacol Ther, 20 (4), 413-21
DOI 10.1111/j.1365-2036.2004.02085.x, PubMed 15298635
Health-related quality of life in patients with inflammatory bowel disease five years after the initial diagnosis
Scand J Gastroenterol, 39 (4), 365-73
DOI 10.1080/00365520310008386, PubMed 15125469
Health-related quality of life in patients with inflammatory bowel disease five years after the inital diagnosis
In Scandinavian journal of gastroenterology, Taylor & Francis, Basingstoke, 39(2004)4, s. 365-73
BIBSYS 051773643
Pediatric inflammatory bowel disease in southeastern Norway: a five-year follow-up study
Digestion, 70 (4), 226-30
DOI 10.1159/000082893, PubMed 15627770
Pediatric inflammatory bowel disease in southeastern Norway: a five year follow-up study
In Digestion, Karger, Basel, 70(2004)4, S. 226-30
BIBSYS 051855887
Publications 2003
Health related quality of life five years after diagnosisin a prospective follow up study of patients with inflammatory bowel disease
In Gut, British Medical Association, London, 52(2003)suppl 6, s.A40
BIBSYS 041729900
Variables influencing health related quality of life in patients with inflammatory bowel disease
In Gastroenterology, Gastroenterology, Baltimore, Md., 124(2003)suppl 1, s.A20 abstrakt S1399
BIBSYS 041729730
Variables influencing health related quality of life (HRQOL) in patients with inflammatory bowel disease (IBD)
In Gastroenterology, Gastroenterology, Baltimore, Md., 124(2003)suppl 1, s.A218 abstrakt S1439
BIBSYS 041729781
Standardization and quality of endoscopy text reports in ulcerative colitis
Endoscopy, 35 (10), 835-40
DOI 10.1055/s-2003-42619, PubMed 14551861
[5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease]
Tidsskr Nor Laegeforen, 123 (18), 2565-7
PubMed 14714043
Familial occurence of IBD
In Gut, British Medical Association, London, 52(2003)suppl 6, s.A79
BIBSYS 04173467x
Familial occurence og IBD in Ulcerative colitis and Crohn's disease patients and the significance of this for disease behaviour
In Gastroenterology, Gastroenterology, Baltimore, Md., 124(2003)suppl 1, s.A210 abstract S1400
BIBSYS 041734653
Publications 2002
Incidence of inflammatory bowel disease in children in southeastern Norway: a prospective population-based study 1990-94
Scand J Gastroenterol, 37 (5), 540-5
DOI 10.1080/00365520252903080, PubMed 12059055
Quality of life in patients with inflammatory bowel disease: translation, data quality, scaling assumptions, validity,reliability and sensitivity to change of the Norwegian version of IBDQ
In Scandinavian journal of gastroenterology, Taylor & Francis, Basingstoke, 37(2002)nr 10, s. 1164-1174
BIBSYS 031388256
Quality of life in patients with inflammatory bowel disease: translation, data quality, scaling assumptions, validity, reliability and sensitivity to change of the Norwegian version of IBDQ
Scand J Gastroenterol, 37 (10), 1164-74
DOI 10.1080/003655202760373371, PubMed 12408521
Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study
Lancet, 359 (9318), 1661-5
DOI 10.1016/S0140-6736(02)08590-2, PubMed 12020527
Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study
In Lancet, Lancet Ltd., London, 359(2002)nr 9318, s. 1661-1665
BIBSYS 031255922
On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole
Scand J Gastroenterol, 37 (6), 642-7
DOI 10.1080/00365520212499, PubMed 12126240
[Colorectal cancer and ulcerative colitis--which patients should be checked?]
Tidsskr Nor Laegeforen, 122 (27), 2624-6
PubMed 12523193
Epidemiology of inflammatory bowel disease--methodological considerations
Dig Liver Dis, 34 (5), 364-9
DOI 10.1016/s1590-8658(02)80131-1, PubMed 12118955
Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study)
J Rheumatol, 29 (3), 511-5
PubMed 11908564
Estimation of Sjögren's syndrome among IBD patients. A six year post-diagnostic prevalence study
Scand J Rheumatol, 31 (3), 140-5
PubMed 12195627
Publications 2001
[Prognosis and treatment of chronic inflammatory bowel disease]
Tidsskr Nor Laegeforen, 121 (3), 318-21
PubMed 11242874
[Pregnancy and labor in ulcerative colitis and Crohn disease]
Tidsskr Nor Laegeforen, 121 (3), 322-5
PubMed 11242875
[Incontinence following emergency surgery and ileoanal anastomosis in ulcerative colitis]
Tidsskr Nor Laegeforen, 121 (11), 1415
PubMed 11419116
[Assessment of the need of 24-hour availability of endoscopy]
Tidsskr Nor Laegeforen, 121 (29), 3396-8
PubMed 11826784
Fibromyalgia and chronic widespread pain in patients with inflammatory bowel disease: a cross sectional population survey
J Rheumatol, 28 (3), 590-4
PubMed 11296964
The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study)
Rheumatology (Oxford), 40 (11), 1256-61
DOI 10.1093/rheumatology/40.11.1256, PubMed 11709609
Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months
Aliment Pharmacol Ther, 15 (3), 347-54
DOI 10.1046/j.1365-2036.2001.00943.x, PubMed 11207509
Quality of health care in inflammatory bowel disease: development of a reliable questionnaire (QUOTE-IBD) and first results
Am J Gastroenterol, 96 (12), 3329-36
DOI 10.1111/j.1572-0241.2001.05334.x, PubMed 11774945
Publications 2000
[Argon plasma coagulation--a new method in therapeutic endoscopy]
Tidsskr Nor Laegeforen, 120 (12), 1413-5
PubMed 10851937
Medical treatment: does it influence the natural course of inflammatory bowel disease?
Eur J Intern Med, 11 (4), 197-203
DOI 10.1016/s0953-6205(00)00091-1, PubMed 10967507
Chronic inflammatory bowel disease and pregnancy
Scand J Gastroenterol, 35 (7), 673-8
DOI 10.1080/003655200750023318, PubMed 10972168
[Reflux disease and 24-hour esophageal pH monitoring in children]
Tidsskr Nor Laegeforen, 120 (2), 183-6
PubMed 10851912
Publications 1999
Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time
Am J Gastroenterol, 94 (6), 1564-9
DOI 10.1111/j.1572-0241.1999.01145.x, PubMed 10364026
Publications 1998
Accuracy of IgG serology and other tests in confirming Helicobacter pylori eradication
Scand J Gastroenterol, 33 (7), 710-5
DOI 10.1080/00365529850171648, PubMed 9712234
Accuracy of seven different tests for the diagnosis of Helicobacter pylori infection and the impact of H2-receptor antagonists on test results
Scand J Gastroenterol, 33 (4), 364-9
DOI 10.1080/00365529850170982, PubMed 9605257
Simplified 10-day bismuth triple therapy for cure of Helicobacter pylori infection: experience from clinical practice in a population with a high frequency of metronidazole resistance
Am J Gastroenterol, 93 (2), 212-6
DOI 10.1111/j.1572-0241.1998.00212.x, PubMed 9468244
Publications 1997
Highly effective second-line anti-Helicobacter pylori therapy in patients with previously failed metronidazole-based therapy
Scand J Gastroenterol, 32 (12), 1209-14
DOI 10.3109/00365529709028149, PubMed 9438318
Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance?
Am J Gastroenterol, 92 (2), 248-53
PubMed 9040200
A comparison between omeprazole-based triple therapy and bismuth-based triple therapy for the treatment of Helicobacter pylori infection: a prospective randomized 1-yr follow-up study
Am J Gastroenterol, 92 (4), 653-8
PubMed 9128317
[Should every patient with ulcerative colitis/Crohn disease be vaccinated against pneumococcal infection?]
Tidsskr Nor Laegeforen, 117 (22), 3262-3
PubMed 9411871
Epidemiology of chronic idiopathic inflammatory bowel disease in south-eastern Norway: a prospective study of the incidence in four counties andrisk factors : The IBSEN study
Department of Internal Medicine, Østfold Central Hospital, Fredrikstad, 1 b. (flere pag.)
BIBSYS 971364230, ISBN 82-7722-069-3
Inflammatory bowel disease: re-evaluation of the diagnosis in a prospective population based study in south eastern Norway
Gut, 40 (3), 328-32
DOI 10.1136/gut.40.3.328, PubMed 9135520
Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease. Results of a large, prospective population-based study in southeastern Norway, 1990-93
Scand J Gastroenterol, 32 (10), 1005-12
DOI 10.3109/00365529709011217, PubMed 9361173
[Gastrointestinal amyloidosis. Differential diagnosis or a complication of inflammatory bowel disease?]
Tidsskr Nor Laegeforen, 117 (24), 3489-91
PubMed 9411905
Publications 1996
Incidence of ulcerative colitis and indeterminate colitis in four counties of southeastern Norway, 1990-93. A prospective population-based study. The Inflammatory Bowel South-Eastern Norway (IBSEN) Study Group of Gastroenterologists
Scand J Gastroenterol, 31 (4), 362-6
DOI 10.3109/00365529609006411, PubMed 8726304
Incidence of Crohn's disease in four counties in southeastern Norway, 1990-93. A prospective population-based study. The Inflammatory Bowel South-Eastern Norway (IBSEN) Study Group of Gastroenterologists
Scand J Gastroenterol, 31 (4), 355-61
DOI 10.3109/00365529609006410, PubMed 8726303
Seasonal variations in the onset of ulcerative colitis
Gut, 38 (3), 376-8
DOI 10.1136/gut.38.3.376, PubMed 8675089
Publications 1995
Incidence of inflammatory bowel disease in southeastern Norway: evaluation of methods after 1 year of registration. Southeastern Norway IBD Study Group of Gastroenterologists
Digestion, 56 (5), 377-81
DOI 10.1159/000201262, PubMed 8549880
IBD in Norway, with special emphasis on the incidence study of southeastern Norway from 1990, initiated in collaboration with the European Community IBD study group
FALK SYMP, 76, 30-36
Publications 1994
[Alternative treatment of Helicobacter pylori infections]
Tidsskr Nor Laegeforen, 114 (12), 1465
PubMed 8079238
Publications 1992
[Natural products can be hazardous to health]
Tidsskr Nor Laegeforen, 112 (10), 1308-11
PubMed 1579916
Publications 1991
[Symptomatic cytomegalovirus infection in patients with acquired immunodeficiency syndrome]
Tidsskr Nor Laegeforen, 111 (28), 3379-84
PubMed 1665253
Fatal cytomegalovirus (CMV) colitis in a patient receiving low dose prednisolone therapy
Scand J Infect Dis, 23 (4), 495-9
DOI 10.3109/00365549109075099, PubMed 1659739
[Cytomegalovirus disease in the gastrointestinal tract]
Tidsskr Nor Laegeforen, 111 (28), 3388-91
PubMed 1665255
[Cytomegalovirus disease in the upper gastrointestinal tract. Endoscopic findings]
Tidsskr Nor Laegeforen, 111 (28), 3391-3
PubMed 1665256
Publications 1984
[Erroneous dosage, overdosage and adverse effects following digoxin administration]
Tidsskr Nor Laegeforen, 104 (24), 1663-4
PubMed 6474444